136 related articles for article (PubMed ID: 8895047)
1. The effect of a very low dose of tolbutamide combined with an alpha-glucosidase inhibitor in non-insulin-dependent diabetes mellitus.
Okada S; Ishii K; Hamada H; Tanokuchi S; Ichiki K; Ota Z
J Int Med Res; 1996; 24(5):433-7. PubMed ID: 8895047
[TBL] [Abstract][Full Text] [Related]
2. The effect of an alpha-glucosidase inhibitor and insulin on glucose metabolism and lipid profiles in non-insulin-dependent diabetes mellitus.
Okada S; Ishii K; Hamada H; Tanokuchi S; Ichiki K; Ota Z
J Int Med Res; 1996; 24(5):438-47. PubMed ID: 8895048
[TBL] [Abstract][Full Text] [Related]
3. Effect of alpha-glucosidase inhibitor in combination with sulphonylurea compounds on lipid profile in patients with non-insulin-dependent diabetes mellitus.
Okada S; Ishii K; Tanokuchi S; Hamada H; Ichiki K; Ota Z
J Int Med Res; 1995; 23(6):492-6. PubMed ID: 8746618
[TBL] [Abstract][Full Text] [Related]
4. Effect of an alpha-glucosidase inhibitor combined with sulphonylurea treatment on glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Okada S; Ishii K; Tanokuchi S; Hamada H; Ichiki K; Ota Z
J Int Med Res; 1995; 23(4):279-83. PubMed ID: 7589771
[TBL] [Abstract][Full Text] [Related]
5. Insulin secretion levels necessary for efficacy of an alpha-glucosidase inhibitor on glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Okada S; Ishii K; Hamada H; Tanokuchi S; Ichiki K; Ota Z
J Int Med Res; 1995; 23(6):497-501. PubMed ID: 8746619
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors.
Bando Y; Ushiogi Y; Okafuji K; Toya D; Tanaka N; Fujisawa M
J Int Med Res; 1999; 27(2):53-64. PubMed ID: 10446691
[TBL] [Abstract][Full Text] [Related]
7. [Combination therapy with sulfonylurea and alpha-glucosidase inhibitor].
Iijima T
Nihon Rinsho; 1997 Nov; 55 Suppl():186-91. PubMed ID: 9434465
[No Abstract] [Full Text] [Related]
8. Can alpha-glucosidase inhibitors reduce the insulin dosage administered to patients with non-insulin-dependent diabetes mellitus?
Okada S; Ishii K; Hamada H; Tanokuchi S; Ichiki K; Ota Z
J Int Med Res; 1995; 23(6):487-91. PubMed ID: 8746617
[TBL] [Abstract][Full Text] [Related]
9. Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients.
Saito N; Sakai H; Suzuki S; Sekihara H; Yajima Y
J Int Med Res; 1998; 26(5):219-32. PubMed ID: 9924706
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of voglibose on daily glycemic excursions assessed by the "J"-index in non-insulin dependent diabetes mellitus.
Yoshioka K; Azukari K; Ashida K; Kasamatsu Y; Yokoo S; Yoshida T; Kondo M
Horm Metab Res; 1997 Aug; 29(8):407-8. PubMed ID: 9288580
[No Abstract] [Full Text] [Related]
11. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
[TBL] [Abstract][Full Text] [Related]
12. Use of an alpha-glucosidase inhibitor to synchronize sugar absorption with delayed insulin secretion in a patient with non-insulin-dependent diabetes mellitus.
Okada S; Ishii K; Tanokuchi S; Hamada H; Ichiki K; Ota Z
J Int Med Res; 1996; 24(1):164-8. PubMed ID: 8674795
[TBL] [Abstract][Full Text] [Related]
13. An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM.
Hara T; Nakamura J; Koh N; Sakakibara F; Takeuchi N; Hotta N
Diabetes Care; 1996 Jun; 19(6):642-7. PubMed ID: 8725865
[TBL] [Abstract][Full Text] [Related]
14. [Sulfonylurea and alpha-glucosidase inhibitor].
Iijima T
Nihon Rinsho; 2002 Sep; 60 Suppl 9():459-63. PubMed ID: 12387034
[No Abstract] [Full Text] [Related]
15. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients.
Matsumoto K; Yano M; Miyake S; Ueki Y; Yamaguchi Y; Akazawa S; Tominaga Y
Diabetes Care; 1998 Feb; 21(2):256-60. PubMed ID: 9539992
[TBL] [Abstract][Full Text] [Related]
16. Can alpha-glucosidase inhibitors reduce the dosage of sulphonylurea compounds needed by patients with non-insulin-dependent diabetes mellitus?
Okada S; Ishii K; Tanokuchi S; Hamada H; Ichiki K; Ota Z
J Int Med Res; 1995; 23(6):502-7. PubMed ID: 8746620
[TBL] [Abstract][Full Text] [Related]
17. Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
Holman RR; Steemson J; Turner RC
Diabetes Res; 1991 Dec; 18(4):149-53. PubMed ID: 1842749
[TBL] [Abstract][Full Text] [Related]
18. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB; Bray GA
Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
[TBL] [Abstract][Full Text] [Related]
19. Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes.
Bao YQ; Zhou M; Zhou J; Lu W; Gao YC; Pan XP; Tang JL; Lu HJ; Jia WP
Clin Exp Pharmacol Physiol; 2011 Jan; 38(1):50-4. PubMed ID: 21083700
[TBL] [Abstract][Full Text] [Related]
20. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
